Rocaglamide

Catalog No.S7428 Batch:S742801

Print

Technical Data

Formula

C29H31NO7
Molecular Weight 505.56 CAS No. 84573-16-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (197.8 mM)
Ethanol 10 mg/mL (19.78 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Rocaglamide (Roc-A), isolated from Aglaia species, is a potent inhibitor of heat shock factor 1 (HSF1) activation with IC50 of ~50 nM for HSF1. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also inhibits NF-κB activity. Rocaglamide exhibits anti-tumor activity.
Targets
eIF4A [1] NF-κB [2] HSF1 [1]
(Cell-free assay)
50 nM
In vitro

Rocaglamide A inhibits the heat shock reporter with IC50 of ~50 nM and inhibits the function of the translation initiation factor eIF4A, a DEAD box RNA helicase.[1] Rocaglamides are able to suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation.[2]
In vivo

Rocaglamide induces apoptosis of tumor cells in SCID mice models. Rocaglamide has the potential to inhibit the growth of HCC cell-derived tumors in vivo.[3]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    MCF7 cells

  • Concentrations

    200 nM

  • Incubation Time

    6 hrs

  • Method

    MCF7 cells are treated with 200 nM rocaglamide A for 6 hrs and RNA is then purified following extraction with TRIzol reagent. Gene expression analysis is performed using Affymetrix GeneChip HT Human Genome U133A 96-Array Plates.
Animal Study:

[3]
  • Animal Models

    6-week-old female SCID mice

  • Dosages

    2.5 mg/kg

  • Administration

    IP

Selleck's Rocaglamide has been cited by 2 publications

Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms [ Elife, 2023, 12e69521] PubMed: 36692000
Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects [ Blood Adv, 2023, 7(12):2926-2937] PubMed: 36827679

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.